QIAstat-Dx syndromic testing system can differentiate novel coronavirus from 20 other respiratory targets Requires less than one minute for sample preparation and delivers results in about one hour ...
PESSAC, France, November 17, 2025--(BUSINESS WIRE)--OCEAN Dx, a pioneer in rapid diagnostic solutions, announced the successful completion of a clinical evaluation study for its innovative rapid ...
ROCKVILLE, Md.--(BUSINESS WIRE)--SYNAPS Dx (SDx) a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), recognizes the ...
REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer Test will ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Please provide your email address to receive an email when new articles are posted on . SYNAPS Dx has announced the opening of a new laboratory to support the launch of DISCERN, a minimally invasive ...
Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has begun shipments to the United States of its new QIAstat-Dx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback